Company: MDCXW
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001062993-25-008292
Chunk: 200

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-01
Form: DRS
Chunk 200
---
 common shares, which number of shares is equal to 19.99% of the aggregate number of common shares issued and outstanding immediately prior to the execution of the SEPA (the "Exchange Cap"), unless (i) we obtain shareholder approval to issue common shares in excess of the Exchange Cap in accordance with applicable Nasdaq rules or (ii) the average price of all applicable sales of common shares under the SEPA equals or exceeds $2.75 per share (which represents the lower of (a) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the Effective Date; or (b) the average Nasdaq Official Closing Price for the five trading days immediately preceding the Effective Date). Moreover, we may not issue or sell any common shares to the Selling Shareholder under the SEPA which, when aggregated with all other common shares then beneficially owned by the Selling Shareholder and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the Selling Shareholder beneficially owning common shares in excess of the 4.99% (the "Ownership Limitation").

Neither we nor the Selling Shareholder may assign or transfer any of our respective rights and obligations under the SEPA without the prior written consent of the other party, and no provision of the SEPA may be modified or waived by the parties other than by an instrument in writing signed by both parties.

The net proceeds from sales, if any, under the SEPA, will depend on the frequency and prices at which we sell common shares to the Selling Shareholder.

As consideration for the Selling Shareholder's commitment to purchase our common shares at our direction upon the terms and subject to the conditions set forth in the SEPA, upon execution of the SEPA, we issued 105,840 Commitment Shares to the Selling Shareholder as set forth in the SEPA.

The SEPA contains customary representations, warranties, conditions, and indemnification obligations of the parties. The representations, warranties, and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.

<div align='center'>- 132 -</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

Advances